USFDA completes inspection at Wanbury’s Patalganga site

18 Jun 2024 Evaluate

United States Food & Drug Administration (USFDA) has completed inspection at Wanbury’s Patalganga site, Maharashtra. USFDA Inspection started from June 10, 2024 and completed on June 14, 2024 with zero-483 observations.

This is 6th successful US FDA inspection of Wanbury Patalganga site. The Company is committed for Quality and compliances as per regulatory requirements at both the API manufacturing sites i.e., Patalganga, Maharashtra and Tanuku, Andhra Pradesh, which is also US FDA approved site. The Company exports APIs to more than 70 countries including US, Europe, Latin America.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.

Wanbury Share Price

283.50 -6.55 (-2.26%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.